newsfilter
← Latest News
Business Wire·

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML